Could ornithine supplementation be beneficial to prevent the formation of pro-atherogenic carbamylated low-density lipoprotein (c-LDL) particles?

Şimşek, Bahadir; Çakatay, Ufuk

doi:10.1016/j.mehy.2019.03.004

Cited by 8 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it has been hypothesized that ornithine may be able to compete with ε-amino groups of lysine residues found in apolipoproteins in their binding to isocyanate, leading to a decrease in cLDL formation[ 66 ]. Finally, it has been shown that flavonoids are able to inhibit LDL carbamylation (probably by scavenging cyanate ions)[ 67 ].…”

Section: Discussionmentioning

confidence: 99%

Carbamylated lipoproteins in diabetes

Denimal¹

2023

World J Diabetes

View full text Add to dashboard Cite

Diabetic dyslipidemia is characterized by quantitative and qualitative abnor-malities in lipoproteins. In addition to glycation and oxidation, carbamylation is also a post-translational modification affecting lipoproteins in diabetes. Patients with type 2 diabetes (T2D) exhibit higher levels of carbamylated low-density lipoproteins (cLDL) and high-density lipoproteins (cHDL). Accumulating evidence suggests that cLDL plays a role in atherosclerosis in diabetes. cLDL levels have been shown to predict cardiovascular events and all-cause mortality. cLDL facilitates immune cell recruitment in the vascular wall, promotes accumulation of lipids in macrophages, and contributes to endothelial dysf-unction, endothelial nitric oxide-synthase (eNOS) inactivation and endothelial repair defects. Lastly, cLDL induces thrombus formation and platelet aggregation. On the other hand, recent data have demonstrated that cHDL serum level is independently associated with all-cause and cardiovascular-related mortality in T2D patients. This relationship may be causative since the atheroprotective properties of HDL are altered after carbamylation. Thus, cHDL loses the ability to remove cholesterol from macrophages, to inhibit monocyte adhesion and recruitment, to induce eNOS activation and to inhibit apoptosis. Taken together, it seems very likely that the abnormalities in the biological functions of LDL and HDL after carbamylation contribute to atherosclerosis and to the elevated cardiovascular risk in diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Carbamylated lipoproteins in diabetes

Denimal¹

2023

World J Diabetes

View full text Add to dashboard Cite

show abstract

“…Recent trials checked L-arginine supplementation in patients with severe asthma and revealed that higher arginine availability index was associated with lower exacerbation events [ 21 ]. Meanwhile, the general use of ornithine has the purpose to support liver function and wound recovery [ 22 , 23 , 24 ]. Systematic pharmacokinetic and pharmacodynamic studies have focused on experimental models of liver failure in patients and resulted in the mechanisms that underpin the effective ammonia-lowering actions of L-ornithine L-aspartate, but little is known about the mechanisms of macrophages modulation.…”

Section: Introductionmentioning

confidence: 99%